SIGN UP
LOG IN
E
ENTO
Entero Therapeutics
0.35
0.01+4.14%After Hours: 0.3380 -0.02 -4.74%19:32 05/01 EDT
OPEN/PREV CLOSE0.3300/0.3407
TODAY RANGE0.3300-0.3549
VOL20.16K
MARKET CAP1.69M
52 WEEK RANGE0.1850-3.160
AVG VOL (3M)656.63K
% TURNOVER0.42%
TURNOVER--
P/E (TTM)-0.0666
% RANGE7.31%
EPS(TTM)-5.3277
P/E(FORWARD)-0.3140
P/B0.0292
BVPS12.16
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.65M
SHARES OUTSTANDING4.77M
NEXT EARNINGS05/12-05/16
FREE FLOAT4.65M
LOT SIZE1
EX-DIV DATE12/18/2023
News
Press Releases
Financial Reports
Profile
Benzinga·04/15 21:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga·04/07 21:05
12 Health Care Stocks Moving In Monday's After-Market Session
TipRanks·04/07 15:55
Biotech Alert: Searches spiking for these stocks today
Benzinga·04/04 12:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga·04/04 09:20
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Benzinga·04/03 21:05
12 Health Care Stocks Moving In Thursday's After-Market Session
TipRanks·04/01 16:19
Entero Therapeutics Delays 10-K Filing
Seeking Alpha·03/25 08:11
Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX
Dow Jones·03/13 12:33
*Vicarious Surgical: Romano Last Served as CFO of Entero Therapeutics >RBOT
TipRanks·03/05 17:16
Biotech Alert: Searches spiking for these stocks today
Seeking Alpha·02/14 21:10
Entero Therapeutics appoints interim CEO
TipRanks·02/14 21:06
Entero Therapeutics names Richard Paolone as interim CEO
Dow Jones·02/14 21:00
Press Release: Entero Therapeutics Appoints Richard Paolone as CEO
TipRanks·02/07 20:40
Entero Therapeutics secures $2M revolving loan, appoints three new directors
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.